Purpose: Using 123I for diagnostic purposes avoids the risk of stunning for subsequent radioiodine treatment and affords an excellent image quality. In this study we assessed the role of 123I in comparison with 131I post-treatment imaging in patients with thyroid cancer.
Methods: We compared a total of 292 123I scans with their corresponding post-treatment 131I images. Patients received a therapeutic dose of 131I following diagnostic scanning with 50-111 MBq of 123I. All patients were in a hypothyroid state (>30 microIU/l) before radioiodine administration for either diagnostic or therapeutic purposes.
Results: In 228 out of 263 patients with a positive diagnostic scan, 123I whole-body scan findings were concordant with those of corresponding post-treatment 131I images (concordance rate 87%). However, there were 44 additional foci of abnormal uptake on post-treatment 131I scans in 22 discordant cases with no impact on therapeutic management of the patients. In 13 patients, there was at least one new site on post-treatment images that had been missed on pretreatment 123I images. Twenty-nine patients with a negative diagnostic scan were treated with 131I owing to a high serum thyroglobulin level (range 11.3-480 ng/ml). Radioiodine uptake sites were seen in eight post-treatment scans. In 21 pairs of whole-body scans, both the pre- and the post-treatment scan were negative (concordance rate 72.4%).
Conclusion: 123I scanning is comparable to high-dose 131I post-treatment imaging in thyroid carcinoma patients, and 123I offers excellent image quality as a diagnostic agent. It avoids disadvantages such as stunning before treatment and delivery of a high radiation dose to patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00259-006-0341-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Retrospective study of post-treatment I SPECT/CT imaging for personalizing therapy of patients with differentiated thyroid cancer.
Folia Med (Plovdiv)
December 2024
Military Medical Academy, Sofia, Bulgaria.
The absence of anatomical landmarks in the whole body scan makes it challenging to precisely localize 131I uptake, which is used to treat patients with differentiated thyroid cancer (DTC). Recently, SPECT/CT studies have been utilized to increase the diagnostic sensitivity and specificity.
View Article and Find Full Text PDFThyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial.
Lancet Diabetes Endocrinol
January 2025
Department of Biostatistics and Epidemiology, Gustave Roussy, Paris, France; University Paris-Saclay, Paris, France; Office of Biostatistics and Epidemiology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Inserm, Université Paris-Saclay, CESP U1018, Oncostat, labelled Ligue Contre le Cancer, Villejuif, France.
Background: ESTIMABL2, a multicentre randomised phase 3 trial in patients with low-risk differentiated thyroid cancer (ie, pT1am or pT1b, N0 [no evidence of regional nodal involvement] or Nx [involvement of regional lymph nodes that cannot be assessed in the absence of neck dissection]), showed the non-inferiority of a follow-up strategy without radioactive iodine (I) administration compared with a postoperative I administration at 3 years post-randomisation. Here, we report a pre-specified analysis after 5 years of follow-up.
Methods: Patients treated with total thyroidectomy with or without prophylactic neck lymph node dissection, without postoperative suspicious findings on neck ultrasonography, were randomly assigned to the no-radioiodine group or to the radioiodine group (1·1 GBq-30 mCi after recombinant human thyrotropin-stimulating hormone).
Low dose radioactive iodine ablation therapy (1.11GBq) for differentiated thyroid cancer in Western Turkey.
Rev Esp Med Nucl Imagen Mol (Engl Ed)
November 2024
Nuclear Medicine Department, Ege University Faculty of Medicine, İzmir, Turkey.
Objective: Ablation therapy is employed in low-risk differentiated thyroid cancer (DTC) cases to facilitate patient monitoring by reducing thyroglobulin (Tg) levels to measurable levels below after surgery by eliminating residual thyroid tissue. However, there is still uncertainty about the minimum activity dose required for effective ablation. Opting for low-dose [131I]-NaI for ablation offers several advantages for both patients and healthcare services.
View Article and Find Full Text PDFResults from a phase I study of 4--[131I]iodo-phenylalanine ([I]IPA) with external radiation therapy in patients with recurrent glioblastoma (IPAX-1).
Neurooncol Adv
July 2024
ABX - CRO Advanced Pharmaceutical Services Forschungsgesellschaft, Dresden, Germany.
Background: Glioblastoma (GBM), the most common malignant brain tumor, is associated with devastating outcomes. IPAX-1 was a multicenter, open-label, single-arm phase I study to evaluate carrier-added 4--[I]iodo-phenylalanine ([I]IPA) plus external radiation therapy (XRT) in recurrent GBM.
Methods: A total of 10 adults with recurrent GBM who had received first-line debulking surgery plus radio-chemotherapy, were randomized to a single-dose regimen (1f; I-IPA 2 GBq before XRT); a fractionated parallel dose regimen (3f-p; 3 I-IPA 670 MBq fractions, in parallel with second-line XRT), or a fractionated sequential dose regimen (3f-s; 3 I-IPA 670 MBq fractions before and after XRT).
Investigation on low-iodine diet implementation by medical staff before radioactive iodine treatment for differentiated thyroid carcinoma.
Ann Nucl Med
August 2024
Department of Nursing, The First Affiliated Hospital of Chongqing Medical University, 1st Youyi Road, Chongqing, 400016, China.
Objective: To explore the implementation of low-iodine diets by medical staff caring for patients with differentiated thyroid carcinoma prior to I therapy across 58 hospitals, and offer valuable insights for the development of guidelines on low-iodine diets.
Methods: Convenience sampling was utilized to conduct a survey among 163 medical staff members working in nuclear medicine departments across 58 tertiary hospitals using a self-designed questionnaire.
Results: Concerning the duration of the low-iodine diet prior to treatment, the medical staff's recommendations were as follows: 58.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!